Glenmark clears phase 3 study on rhinitis treatment
The company had been studying Ryaltris, a nasal spray, for the treatment of seasonal allergic rhinitis
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Lupin to sell Aptissen products in Canada
Lupin has been granted immediate distribution rights in Canada for Synolis VA, an injection used for the treatment of…
Research Point Global and WuXi CDS to rebrand as WuXi Clinical
The newly combined CRO specializes in collaborative partnering for global clinical trials
Indoco’s new solid dosages facility at Baddi receives UK-MHRA approval
The plant, which was established in 2016, had its first ever regulatory inspection in October, 2018
Natco Pharma’s marketing partner gets USFDA approval for chest pain tablets
The company's marketing partner, Alvogen, received ANDA approval from USFDA for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4…
Biocon, partnering with Mylan, to share profits in global commercialisation of Hulio
The pharma major had earlier retained economic interest in the European sales of Hulio, (biosimilar Adalimumab), which is…
Alembic partners with SPH Group and Adia for Chinese market
The JV will commercialise products in the Chinese market which has an increasing demand for generic drugs
Lupin receives tentative USFDA approval for Fosaprepitant for Injection
The company can now market a generic version of Merck's Emend for Injection, 150 mg Single-Dose Vial
Yasir Rawjee appointed as CEO of Glenmark Life Sciences
Rawjee, who will now head the company's newly created API unit, was previously Head of Global API Operations at Mylan Inc
Hester Biosciences recommends a final dividend of INR 7 per share
The company declared its consolidated financial report, registering a 44 per cent hike in profit margins for FY19